Celltrion上半年收入创新高并称全年有望超过5.3万亿韩元收入目标

Celltrion (068270.KS) posted its highest-ever first-half revenue, driven by growth in sales of high-margin new products. The company expects to exceed the annual revenue target of 5.3 trillion won and operating profit target of 1.8 trillion won it set at the start of the year.
Celltrion reported first-half revenue of 2.5387 trillion won and operating profit of 773.7 billion won, the company said in a regulatory filing on the 27th. Revenue rose 40.77% and operating profit surged 97.42% from a year earlier. In the second quarter, revenue reached 1.3937 trillion won and operating profit 451.8 billion won, up 45.0% and 86.3% respectively from a year earlier. Following the first quarter, the second quarter marked another record quarterly revenue, exceeding the preliminary results announced on the 3rd of this month by 93.7 billion won in revenue and 21.8 billion won in operating profit.
Celltrion attributed the results to a shift in its product portfolio toward new products. Second-quarter sales of products classified as new — Remsima SC, Yuflyma, Vegzelma, Steqeyma, Stoboclo, Osenvelt, Avtozma, Omlyclo and Eydenzelt — grew 76% from a year earlier. As a result, their share of total bio product sales expanded to 65%. The company plans to raise the sales share of new products to 70% in the second half by expanding the countries where the products are launched and their indications. In addition, the second-quarter cost of goods sold ratio improved 5.4 percentage points from a year earlier to 38%.
Celltrion aims to exceed the annual revenue target of 5.3 trillion won and operating profit target of 1.8 trillion won it set at the start of the year. "As we begin full-scale supply of bid volumes in major countries in the second half and expand the market share of new products, we expect earnings growth exceeding the first half," a Celltrion official said.
Meanwhile, Celltrion plans to build a portfolio of a total of 18 products by 2030. To that end, it is developing biosimilars of autoimmune disease treatments such as Ocrevus, Cosentyx and Taltz, and anticancer drugs such as Keytruda and Darzalex. Alongside this, in the new drug segment, the company continues to expand a diverse portfolio including antibody-drug conjugates (ADCs), multispecific antibodies and obesity treatments through its own research and development and open innovation. "We will do our best to enhance mid- to long-term corporate value by continuously reinvesting the stable cash flow generated from biosimilars into follow-up products and new drug development," a Celltrion official added.